Inhibition of nitric oxide formation by aminoguanidine: An attempt to prevent insulin-dependent diabetes mellitus

General Pharmacology

Volumn 29, Issue 5, 1997, Pages 697-700

  Holstad, Maria ^a   Jansson, Leif ^a   Sandler, Stellan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

cells; Aminoguanidine; Insulin dependent diabetes mellitus; Nitric oxide; Nitric oxide synthase

Indexed keywords

AMINOGUANIDINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; GUANIDINES; HUMANS; ISLETS OF LANGERHANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 0030667102     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(97)00012-8     Document Type: Review

References (50)

1. Bendtzen K. (1989) Immune hormones (cytokines): pathogenic role in autoimmune rheumatic and endocrine disease. Autoimmunity 2, 177-189.
2. Brian J. E. Jr, Helstad D. D. and Faraci F. M. (1995) Mechanisms of endotoxin-induced dilatation of cerebral arterioles. Am. J. Physiol. 269, H783-H788.
3. Brownlee M., Vlassara H., Kooney A., Ulrich P. and Cerami A. (1986) Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232, 1629-1632.
4. Conger J., Robinette J., Villar A., Raij L. and Schultz P. (1995) Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats. J. Clin. Invest. 96, 631-638.
5. Corbett J. A. and McDaniel M. L. (1992) Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41, 897-903.
6. Corbett J. A. and McDaniel M. L. (1996) Selective inhibition of inducible nitric oxide synthase by aminoguanidine. Methods Enzymol. 268, 398-408.
7. Corbett J. A., Mikhael A., Shimizu J., Frederick K., Misko T. P., McDaniel M. L., Kanagawa O. and Unanue E. R. (1993) Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and -resistant stages in the immunological diabetic prccess. Proc. Natl. Acad. Sci. USA 90, 8992-8995.
8. Cross A. H., Misko T. P., Lin R. F., Hickey W. F., Trotter J. L. and Tilton R. G. (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J. Clin. Invest. 93, 2684-2690.
9. Eisenbarth G. S. (1986) Type 1 diabetes mellitus: a chronic autoimmune disease. N. Engl. J. Med. 314, 1360-1368.
10. Eizirik D. L., Flodström M., Karlsen A. E. and Welsh N. (1996) The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia 39, 875-890.
11. Eizirik D. L., Sandler S., Welsh N., Cetkovic C. M., Nieman A., Geller D. A., Pipeleers D. G., Bendtzen K. and Hellerström C. (1994) Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J. Clin. Invest. 93, 1968-1974.
12. G-methylarginine. Biochem. Biophys. Res. Commun. 170, 96-103.
13. Holstad M., Jansson L. and Sandier S. (1996) Effects of aminoguanidine on rat pancreatic islets in culture and on the pancreatic islet blood flow of anaesthetized rats. Biochem. Pharmac. 51, 1711-1717.
14. Holstad M. and Sandler S. (1993) Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 15, 311-314.
15. Jansson L. (1994) The regulation of pancreatic islet blood flow. Diabetes Metab. Rev. 10, 407-416.
16. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem. Biophys. Res. Commun. 199, 147-154.
17. Kamijo R., Harada H., Matsuyama T., Bosland M., Gerecitano J., Shapiro D., Le J., Koh S. I., Kimura T. and Green S. J. (1994) Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263, 1612-1615.
18. Kolb H., Kiesel U., Kroncke K. D. and Kolb B. V. (1991) Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci. 49, PL213-PL2177.
19. Kolb-Bachofen V., Epstein S., Kiesel U. and Kolb H. (1988) Low-dose streptozocin-induced diabetes in mice: electron microscopy reveals single-cell insulitis before diabetes onset. Diabetes 37, 21-27.
20. Lambert L. E., Whitten J. P., Baron B. M., Cheng H. C., Doherty N. S. and McDonald I. A. (1991) Nitric oxide synthesis in the CNS endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues. Life Sci. 48, 69-75.
21. Lee K. U., Kim M. K., Amano K., Pak C. Y., Jaworski M. A., Mehta J. G. and Yoon J.-W. (1988) Preferential infiltration of macrophages during early stages of insulitis in diabetes-prone BB rats. Diabetes 37, 1053-1058.
22. Lindsay R. M., Smith W., Rossiter S. P., McIntyre M. A., Williams B. C. and Baird J. D. (1995) N-Nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes 44, 365-368.
23. Lopez B. J. and Whittle B. J. (1995) Aminoguanidine-provoked leukocyte adherence to rat mesenteric venules: role of constitutive nitric oxide synthase inhibition. Br. J. Pharmac. 116, 2710-2714.
24. Lowenstein C. J., Dinerman J. L. and Snyder S. H. (1994) Nitric oxide: a physiologic messenger. Ann. Intern. Med. 120, 227-237.
25. Lukic M. L., Stosic G. S., Ostojic N., Chan W. L. and Liew F. Y. (1991) Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem. Biophys. Res. Commun. 178, 913-920.
26. Mandrup-Poulsen T. (1996) The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 39, 1005-1029.
27. Meijer F., Ruijter J. M., Van Delft J. L. and Van Haeringen N. J. (1995) Nitric oxide induces vascular permeability changes in the guinea pig conjunctiva. Eur. J. Pharmac. 284, 61-67.
28. Misko T. P., Moore W. M., Kasten T. P., Nickols G. A., Corbett J. A., Tilton R. G., McDaniel M. L., Williamson J. R. and Currie M. G. (1993) Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmac. 233, 119-125.
29. Moncada S., Palmer R. and Higgs E. (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmac. Rev. 43, 109-142.
30. Nerup J., Mandrup-Poulsen T. and Molvig J. (1987) The HLA-IDDM association: implications for etiology and pathogenesis of IDDM. Diabetes Metab. Rev. 3, 779-802.
31. Ou P. and Wolff S. P. (1993) Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem. Pharmac. 46, 1139-1144.
32. Palmer R. M. J., Ferrige A. G. and Moncada S. (1987) Nitric oxide release accounts for the biological activity of endothelial-derived relaxing factor. Nature 327, 524-526.
33. Rabinovitch A. (1993) Roles of cytokines in IDDM pathogenesis and islet β-cell destruction. Diabetes Rev. 1, 215-240.
34. Rees D. D., Palmer R. M. J., Schulz R., Hodson H. F. and Moncada S. (1990) Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmac. 101, 746-752.
35. Sandier S., Eizirik D. L., Svensson C., Strandell E., Welsh M. and Welsh N. (1991) Biochemical and molecular actions of interleukin-1 on pancreatic β-cells. Autoimmunity 10, 241-253.
36. Schmidt H. H. H. W., Warner T. D., Ishii K., Sheng H. and Murad F. (1992) Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 255, 721-723.
37. Southern C., Schulster D. and Green I. C. (1990) Inhibition of insulin secretion by interleukin-1 beta and tumour necrosis factor-alpha via an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett. 276, 42-44.
38. Stuehr D. J. and Marletta M. A. (1987) Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J. Immunol. 139, 518-525.
39. Suschek C., Fehsel K., Kröncke K.-D., Sommer A. and Kolb-Bachofen V. (1994) Primary cultures of rat islet capillary endothelial cells: constitutive and cytokine-inducible macrophagelike nitric oxide synthases are expressed and activities regulated by glucose concentration. Am. J. Pathol. 145, 685-695.
40. G-nitro-L-arginine causes a preferential decrease in pancreatic islet blood flow in normal rats and spontaneously diabetic GK rats. Endocrinology 135, 849-853.
41. Svensson A. M., Sandler S. and Jansson L. (1995) The blood flow in pancreatico-duodenal grafts in rats: inhibition of nitric oxide synthase preferentially decreases islet blood flow. Eur. J. Pharmac. 275, 99-103.
42. Tasaka Y., Nakaya F., Matsumoto H. and Omori Y. (1994) Effects of aminoguanidine on insulin release from pancreatic islets. Endoc. J. 41, 309-313.
43. Tilton R. G., Chang K., Hasan K. S., Smith S. R., Petrash J. M., Misko T. P., Moore W. M., Currie M. G., Corbett J. A. and McDaniel M. L. (1993) Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42, 221-232.
44. Vincent S. R. (1992) Nitric oxide and arginine-evoked insulin secretion. Science 258, 1376-1378.
45. Welsh N., Eizirik D. L., Bendtzen K. and Sandler S. (1991) Interleukin-1-β-induced nitric oxide production in isolated rat pancreatic islets requires gene transcription and may lead to inhibition of the Krebs cycle enzyme aconitase. Endocrinology 129, 3167-3173.
46. Wolff D. J. and Lubeskie A. (1995) Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch. Biochim. Biophys. 316, 290-301.
47. Worrall N. K., Chang K., Allison W. S., Misko T. P., Sullivan P. M., Tilton R. G., Williamson J. R. and Ferguson T. B. Jr. (1996) Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ. Res. 78, 769-779.
48. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44, 360-364.
49. Zähner D. and Malaisse W. J. (1992) Effects of advanced glycation products and aminoguanidine upon insulin release. Diabetes Nutr. Metab. 5, 43-46.
50. Zhang F., Casey R. M., Ross M. E. and Iadecola C. (1996) Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke 27, 317-323.